Page 7,058«..1020..7,0577,0587,0597,060..7,0707,080..»

New high definition fiber tracking reveals damage caused by traumatic brain injury

Posted: Published on March 2nd, 2012

ScienceDaily (Mar. 2, 2012) A powerful new imaging technique called High Definition Fiber Tracking (HDFT) will allow doctors to clearly see for the first time neural connections broken by traumatic brain injury (TBI) and other neurological disorders, much like X-rays show a fractured bone, according to researchers from the University of Pittsburgh in a report published online in the Journal of Neurosurgery. In the report, the researchers describe the case of a 32-year-old man who wasn't wearing a helmet when his all-terrain vehicle crashed. Initially, his CT scans showed bleeding and swelling on the right side of the brain, which controls left-sided body movement. A week later, while the man was still in a coma, a conventional MRI scan showed brain bruising and swelling in the same area. When he awoke three weeks later, the man couldn't move his left leg, arm and hand. "There are about 1.7 million cases of TBI in the country each year, and all too often conventional scans show no injury or show improvement over time even though the patient continues to struggle," said co-senior author and UPMC neurosurgeon David O. Okonkwo, M.D., Ph.D., associate professor, Department of Neurological Surgery, Pitt School of Medicine. "Until … Continue reading

Posted in Brain Injury Treatment | Comments Off on New high definition fiber tracking reveals damage caused by traumatic brain injury

Local MS sufferers lament government inaction

Posted: Published on March 2nd, 2012

Select a Publication: N E W S P A P E R S ---------------------------------------------- ---Alberta--- Airdrie - Airdrie Echo Banff - Banff Crag and Canyon Beaumont - Beaumont News Calgary - The Calgary Sun Camrose - Camrose Canadian Canmore - Canmore Leader Central Alberta - County Market Cochrane - Cochrane Times Cold Lake - Cold Lake Sun Crowsnest Pass - Crowsnest Pass Promoter Devon - Dispatch News Drayton - Drayton Valley Western Review Edmonton - Edmonton Examiner Edmonton - The Edmonton Sun Edson - Edson Leader Fairview - Fairview Post Fort McMurray - Fort McMurray Today Fort Saskatchewan - Fort Saskatchewan Record Grande Prairie - Daily Herald Tribune Hanna - Hanna Herald High River - High River Times Hinton - Hinton Parklander Lacombe - Lacombe Globe Leduc - Leduc Representative Lloydminster - Meridian Booster Mayerthorpe - Mayerthorpe Freelancer Nanton - Nanton News Peace Country - Peace Country Sun Peace River - Peace River Record Gazette Pincher Creek - Pincher Creek Echo Sherwood Park - Sherwood Park News Spruce Grove - Spruce Grove Examiner Stony Plain - Stony Plain Reporter Strathmore - Strathmore Standard Vermilion - Vermilion Standard Vulcan - Vulcan Advocate Wetaskiwin - Wetaskiwin Times Whitecourt - Whitecourt Star ---Manitoba--- … Continue reading

Posted in MS Treatment | Comments Off on Local MS sufferers lament government inaction

DNA to Be Sequenced for Patients with Rare Diseases

Posted: Published on March 2nd, 2012

Newswise Rare genetic diseases, long overlooked because they affect relatively few people, are getting new attention. Scientists at Washington University School of Medicine in St. Louis are reaching out to patient advocacy groups and offering to decode the DNA of 99 patients with rare diseases to help find the genetic alterations responsible for their illnesses. The patients DNA will be sequenced at the universitys Genomics and Pathology Services (GPS) at no cost to patients or the advocacy groups. The new effort is known as the Rare99X Clinical Exome Challenge. The genomics revolution provides many of the tools that may unlock the secrets of rare diseases, says Jimmy Lin, PhD, research instructor in pathology and immunology. We are excited to form partnerships with patient advocacy groups to apply these technologies to advance clinical understanding of these diseases. Collectively, an estimated 7,000 rare diseases affect some 25 million Americans. They range from Huntingtons disease, a neurodegenerative disorder diagnosed in adulthood, to Neimann-Pick, a metabolic disorder which can occur in infancy. In recent years, advances in technology have made DNA sequencing cheaper, faster and more accurate. For patients with rare diseases, scientists now can use that technology to find the genetic error or … Continue reading

Comments Off on DNA to Be Sequenced for Patients with Rare Diseases

Research and Markets: Artificial cells, Cell Engineering and Therapy

Posted: Published on March 2nd, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets(http://www.researchandmarkets.com/research/ad83a7/artificial_cells) has announced the addition of Woodhead Publishing Ltd's new book "Artificial cells, cell engineering and therapy" to their offering. Artificial cells, cell engineering and therapy are emerging technologies which will make a significant impact on the future of medicine and healthcare. However, research within the field is vast. This unique book provides a comprehensive study of the most recent advances in the field and its practical applications. The first part of the book offers the reader an introduction to the basics of artificial cell technology with chapters on its origins, design and current status within medicine and future prospects. Part 2 covers apoptosis, the use of bone marrow stromal cells in myocardial regeneration together with signalling and tissue engineering. Part 3 discusses artificial cells for therapy, procedures for various clinical conditions and the current status of the discipline within the field. The book concludes with a final section on the role of artificial cells in medicine with particular focus on the use of artificial cells as blood substitutes and their potential use in myocardial regeneration, drug delivery and in treating kidney and bowel diseases, diabetes and cancer. Key Topics Covered: For more information visit http://www.researchandmarkets.com/research/ad83a7/artificial_cellsContinue reading

Comments Off on Research and Markets: Artificial cells, Cell Engineering and Therapy

Cord Blood Registery Helps Families Use Stem Cells – Video

Posted: Published on March 2nd, 2012

29-02-2012 17:57 Learn more at http://www.cordblood.com CBR's team of dedicated professionals is prepared to guide you through every step of the banking process and beyond. Meet Sherry, CBR's transplant coordinator. As Sherry says, her employer is CBR, but she works for the families who need newborn stem cell medicine. She is the voice parents hear over the phone when they need to use their stored cord blood stem cells. Sherry's dedication and passion to deliver exceptional customer service to clients is one example of the many people at Cord Blood Registry who are committed to helping families live longer, healthier lives. Continued here: Cord Blood Registery Helps Families Use Stem Cells - Video … Continue reading

Posted in Cell Medicine | Comments Off on Cord Blood Registery Helps Families Use Stem Cells – Video

UCLA Scientists Identify Cell and Signaling Pathway that Regulates the Placental Blood Stem Cell Niche

Posted: Published on March 2nd, 2012

Newswise UCLA stem cell researchers have discovered a critical placental niche cell and signaling pathway that prevent blood precursors from premature differentiation in the placenta, a process necessary for ensuring proper blood supply for an individuals lifetime. The placental niche, a stem cell safe zone, supports blood stem cell generation and expansion without promoting differentiation into mature blood cells, allowing the establishment of a pool of precursor cells that provide blood cells for later fetal and post-natal life, said study senior author Dr. Hanna Mikkola, an associate professor of molecular cell and developmental biology and a researcher at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Mikkola and her team found that PDGF-B signaling in trophoblasts, specialized cells of the placenta that facilitate embryo implantation and gas and nutrient exchanges between mother and fetus, is vital to maintaining the unique microenvironment needed for the blood precursors. When PDGF-B signaling is halted, the blood precursors differentiate prematurely, creating red blood cells in the placenta, Mikkola said. The study, done in mouse models, appears March 1, 2012, in the peer-reviewed journal Developmental Cell. We had previously discovered that the placenta provides a home for a … Continue reading

Posted in Cell Medicine | Comments Off on UCLA Scientists Identify Cell and Signaling Pathway that Regulates the Placental Blood Stem Cell Niche

UCLA scientists identify crucial cell and signaling pathway in placental blood stem cell niche

Posted: Published on March 2nd, 2012

Public release date: 1-Mar-2012 [ | E-mail | Share ] Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Health Sciences UCLA stem cell researchers have discovered a critical placental niche cell and signaling pathway that prevent blood precursors from premature differentiation in the placenta, a process necessary for ensuring proper blood supply for an individual's lifetime. The placental niche, a stem cell "safe zone," supports blood stem cell generation and expansion without promoting differentiation into mature blood cells, allowing the establishment of a pool of precursor cells that provide blood cells for later fetal and post-natal life, said study senior author Dr. Hanna Mikkola, an associate professor of molecular cell and developmental biology and a researcher at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Mikkola and her team found that PDGF-B signaling in trophoblasts, specialized cells of the placenta that facilitate embryo implantation and gas and nutrient exchanges between mother and fetus, is vital to maintaining the unique microenvironment needed for the blood precursors. When PDGF-B signaling is halted, the blood precursors differentiate prematurely, creating red blood cells in the placenta, Mikkola said. The study, done in mouse models, … Continue reading

Posted in Cell Medicine | Comments Off on UCLA scientists identify crucial cell and signaling pathway in placental blood stem cell niche

Cell and signaling pathway that regulates the placental blood stem cell niche identified

Posted: Published on March 2nd, 2012

ScienceDaily (Mar. 1, 2012) UCLA stem cell researchers have discovered a critical placental niche cell and signaling pathway that prevent blood precursors from premature differentiation in the placenta, a process necessary for ensuring proper blood supply for an individual's lifetime. The placental niche, a stem cell "safe zone," supports blood stem cell generation and expansion without promoting differentiation into mature blood cells, allowing the establishment of a pool of precursor cells that provide blood cells for later fetal and post-natal life, said study senior author Dr. Hanna Mikkola, an associate professor of molecular cell and developmental biology and a researcher at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Mikkola and her team found that PDGF-B signaling in trophoblasts, specialized cells of the placenta that facilitate embryo implantation and gas and nutrient exchanges between mother and fetus, is vital to maintaining the unique microenvironment needed for the blood precursors. When PDGF-B signaling is halted, the blood precursors differentiate prematurely, creating red blood cells in the placenta, Mikkola said. The study, done in mouse models, appears March 1, 2012, in the peer-reviewed journal Developmental Cell. "We had previously discovered that the placenta provides a … Continue reading

Posted in Cell Medicine | Comments Off on Cell and signaling pathway that regulates the placental blood stem cell niche identified

Advanced Cell Technology Announces 2011 Financial Results

Posted: Published on March 2nd, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT, OTCBB: ACTC), a leader in the field of regenerative medicine, today announced year-end results for the year ended December 31, 2011. The Company utilized $13.6 million in cash for operations during the year, compared to $8.8 million in the year-earlier period. The increase in cash utilization resulted primarily from ACTs ongoing clinical activities in the US and Europe. ACT ended the year with cash and cash equivalents of $13.1 million, compared to $15.9 million in cash and cash equivalents in the year-earlier period. Some of the 2011 highlights included: 2011 was a very important and successful year for ACT as we began our Phase 1/2 trials for the treatment of macular degeneration, said Gary Rabin, chairman and CEO of ACT. We are very excited about the preliminary Phase 1/2 clinical data from our dry-AMD and Stargardts disease trials, which were published in The Lancet earlier this year. The data demonstrated the safety of ACTs human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells for the treatment of both diseases. The vision of both patients appears to have improved after transplantation, and no adverse safety issues have been observed. We look forward … Continue reading

Posted in Cell Medicine | Comments Off on Advanced Cell Technology Announces 2011 Financial Results

Research and Markets: Artificial cells, Cell Engineering and Therapy

Posted: Published on March 2nd, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets(http://www.researchandmarkets.com/research/ad83a7/artificial_cells) has announced the addition of Woodhead Publishing Ltd's new book "Artificial cells, cell engineering and therapy" to their offering. Artificial cells, cell engineering and therapy are emerging technologies which will make a significant impact on the future of medicine and healthcare. However, research within the field is vast. This unique book provides a comprehensive study of the most recent advances in the field and its practical applications. The first part of the book offers the reader an introduction to the basics of artificial cell technology with chapters on its origins, design and current status within medicine and future prospects. Part 2 covers apoptosis, the use of bone marrow stromal cells in myocardial regeneration together with signalling and tissue engineering. Part 3 discusses artificial cells for therapy, procedures for various clinical conditions and the current status of the discipline within the field. The book concludes with a final section on the role of artificial cells in medicine with particular focus on the use of artificial cells as blood substitutes and their potential use in myocardial regeneration, drug delivery and in treating kidney and bowel diseases, diabetes and cancer. Key Topics Covered: For more information visit http://www.researchandmarkets.com/research/ad83a7/artificial_cellsContinue reading

Posted in Cell Therapy | Comments Off on Research and Markets: Artificial cells, Cell Engineering and Therapy

Page 7,058«..1020..7,0577,0587,0597,060..7,0707,080..»